Inavolisib combination reduces PFS advanced HR+, HER2- breast cancer with PIK3CA mutation

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.

March 13, 2026

Vol.52 No.10

Cancer Policy

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

Mount Sinai hospital has formed a committee to investigate the ties between Jeffrey Epstein and Eva Dubin a leading doctor at the hospital and founder of the Dubin Breast Center at the Tisch Cancer Institute whose name is featured prominently in the Epstein files.

March 06, 2026

Vol.52 No.09

By Claire Marie Porter and Sara Willa Ernst

Clinical Roundup

TNBC can become resistant to therapy in more than one way, Baylor study finds

About 50% of triple-negative breast cancer patients develop resistance to therapy. When resistance arises, tumors are more likely to come back after the original treatment, significantly reducing the chances of survival.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

Inavolisib combination reduces PFS advanced HR+, HER2- breast cancer with PIK3CA mutation

YOU MAY BE INTERESTED IN

As more people are surviving cancer, we must continue funding bold science

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

TNBC can become resistant to therapy in more than one way, Baylor study finds

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login